✦ LIBER ✦

A pilot study of concurrent radiation, mitomycin-C and 5-FU in marginally operable carcinomas of the rectum

✍ Scribed by Ben Sischy; Raman Qazi; E.Josephine Hinson

Publisher: Elsevier Science
Year: 1984
Tongue: English
Weight: 99 KB
Volume: 10
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(84)90686-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined radiation therapy, mitomycin C,

Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: Results of a pilot study

✍ C.S. Wong; B.J. Cummings; T.J. Keane; W. Dobrowsky; B. O'Sullivan; C.N. Catton 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 682 KB

Concurrent radiation, mitomycin C and 5-

Concurrent radiation, mitomycin C and 5-fluorouracil in poor prognosis carcinoma of cervix: Preliminary results of a phase I-II study

✍ Gillian Thomas; Alon Dembo; Francis Beale; Helen Bean; Raymond Bush; James Herma 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 701 KB

The role of intraluminal radiotherapy an

The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: A pilot study

✍ Dr. Ketayun A. Dinshaw; Vinay Sharma; Anil M. Pendse; Champat S. Telang; Shanti 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

Synchronous 5-fluorouracil, mitomycin-c

Synchronous 5-fluorouracil, mitomycin-c and radiation therapy in the treatment of locally advanced carcinoma of the cervix

✍ S.M. Ludgate; A.J. Crandon; C.N. Hudson; Q. Walker; A.O. Langlands 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 924 KB

Cisplatin, etoposide, and mitomycin in t

Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study

✍ Stephen Davis; Maurizio Tomato; Lucio Crino; Mari Antonetta Colozza; Kenneth Lub 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin. A major response rate (complete response + partial response) was seen in 15 patients (39%). Median survival for all patients was 340 days; median survival of the responding

5FU infusion with mitomycin-C versus 5FU

5FU infusion with mitomycin-C versus 5FU infusion with methyl-CCNU in the treatment of advanced colon cancer. A southwest oncology group study

✍ Thomas Buroker; P. N. Kim; Carl Groppe; Joseph McCracken; Robert O'Bryan; Frank 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 2 views